SNAP-8 Import Supplier — Colombia
Research Use Only: All compounds supplied by Aarise Healthcare are strictly for laboratory research and scientific investigation. Not intended for human consumption, therapeutic use, or clinical application. All purchases must comply with applicable local laws and regulations.
Aarise Healthcare exports SNAP-8 (CAS: 868844-74-0) to research institutions in Colombia. Our WHO-GMP certified facility in India supplies 98%+ purity SNAP-8 for acetylcholine receptor antagonism and wrinkle research.
SNAP-8 Export Specifications for Colombia
| Compound | SNAP-8 |
| CAS Number | 868844-74-0 |
| Purity | 98%+ (HPLC verified) |
| Form | Lyophilised powder |
| Regulatory Reference | INVIMA |
| Shipping | DHL/FedEx temperature-controlled |
| Transit to Colombia | 5-10 business days |
| Documentation | CoA, HPLC, MS, export docs |
Research Applications of SNAP-8
SNAP-8 is used in acetylcholine receptor antagonism and wrinkle research. Research institutions in Colombia source this compound for preclinical studies under applicable INVIMA research regulations.
Why Colombia Researchers Source SNAP-8 from India
- WHO-GMP certified Indian manufacturer — internationally recognised compliance
- Competitive pricing for bulk research quantities
- Full export documentation package for INVIMA compliance
- Temperature-controlled DHL/FedEx shipping to Colombia
- Dedicated international research supply team
- 98%+ purity guaranteed with independent third-party CoA
Related Peptides in Colombia
Semaglutide in Colombia | Tirzepatide in Colombia | Retatrutide in Colombia | Liraglutide in Colombia
SNAP-8 — Other Countries
SNAP-8 in USA | SNAP-8 in UK | SNAP-8 in Germany | SNAP-8 in Australia
Source from India — Key Manufacturing Cities
SNAP-8 in Mumbai, India | SNAP-8 in Delhi, India | SNAP-8 in Hyderabad, India | SNAP-8 in Bangalore, India
Request SNAP-8 for your Colombia research facility: Send your institution details and quantity requirements. We respond within 24 hours with FOB pricing and export documentation.
